Figure 5.
Figure 5. DFS of 31 patients who underwent high-dose 90Y-ibritumomab tiuxetan and ASCT in NHL, based on histology.

DFS of 31 patients who underwent high-dose 90Y-ibritumomab tiuxetan and ASCT in NHL, based on histology.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal